Zobrazeno 1 - 10
of 420
pro vyhledávání: '"Jason Karlawish"'
Publikováno v:
BMC Digital Health, Vol 2, Iss 1, Pp 1-11 (2024)
Abstract Widespread adoption of digital health tools has the potential to improve health and health care for individuals and their communities, but realizing this potential requires anticipating and addressing numerous ethical and regulatory challeng
Externí odkaz:
https://doaj.org/article/4d77c1241c1d4241a306af7c8eb27a7a
Autor:
Jason Karlawish, Joshua D. Grill
Publikováno v:
EBioMedicine, Vol 108, Iss , Pp 105291- (2024)
Summary: Advances in treatment are changing not only the therapeutic options for patients with Alzheimer's disease; they're also changing their diagnostic options. Technologies to detect amyloid such as PET imaging and blood or CSF testing now have a
Externí odkaz:
https://doaj.org/article/901efd0a24214edc864e493908c21c37
Autor:
Zachary Beattie, Lyndsey M. Miller, Carlos Almirola, Wan-Tai M. Au-Yeung, Hannah Bernard, Kevin E. Cosgrove, Hiroko H. Dodge, Charlene J. Gamboa, Ona Golonka, Sarah Gothard, Sam Harbison, Stephanie Irish, Judith Kornfeld, Jonathan Lee, Jennifer Marcoe, Nora C. Mattek, Charlie Quinn, Christina Reynolds, Thomas Riley, Nathaniel Rodrigues, Nicole Sharma, Mary Alice Siqueland, Neil W. Thomas, Timothy Truty, Rachel Wall, Katherine Wild, Chao-Yi Wu, Jason Karlawish, Nina B. Silverberg, Lisa L. Barnes, Sara Czaja, Lisa C. Silbert, Jeffrey Kaye
Publikováno v:
Digital Biomarkers, Vol 4, Iss 1, Pp 100-118 (2020)
Introduction: Future digital health research hinges on methodologies to conduct remote clinical assessments and in-home monitoring. The Collaborative Aging Research Using Technology (CART) initiative was introduced to establish a digital technology r
Externí odkaz:
https://doaj.org/article/303f4d042ced437491356dcb5bf5f1e5
Reactions to learning a 'not elevated' amyloid PET result in a preclinical Alzheimer’s disease trial
Publikováno v:
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-8 (2018)
Abstract Background The experiences of biomarker-ineligible cognitively normal persons can inform trial conduct and the translation of preclinical Alzheimer’s disease (AD) into clinical practice. Methods We interviewed 33 persons whose “not eleva
Externí odkaz:
https://doaj.org/article/713a39a5a5f04845b191ad3758bfb70c
Autor:
Bonnie Wong, Diane Lucente, Samantha Krivensky, Erin Krahn, Jason Karlawish, Bradford C. Dickerson
Publikováno v:
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 13, Iss 1, Pp n/a-n/a (2021)
Abstract Introduction The decision to undergo genetic testing for familial frontotemporal dementia (fFTD) is challenging and complex. When counseling individuals, clinicians need to know what individuals understand about the type of fFTD for which th
Externí odkaz:
https://doaj.org/article/82b03b1326c843f9b730399bf7afbaca
Autor:
Emily A Largent, Kristin Harkins, Christopher H van Dyck, Sara Hachey, Pamela Sankar, Jason Karlawish
Publikováno v:
PLoS ONE, Vol 15, Iss 2, p e0229137 (2020)
ImportanceClinical guidelines currently recommend against amyloid imaging for cognitively unimpaired persons. The goal of Alzheimer's disease (AD) prevention, together with advances in understanding the pathophysiology of AD, however, has led to tria
Externí odkaz:
https://doaj.org/article/6b41f043294f49e49dad566b6ad64551
Autor:
Kurt D. Christensen, Jason Karlawish, J. Scott Roberts, Wendy R. Uhlmann, Kristin Harkins, Elisabeth M. Wood, Thomas O. Obisesan, Lan Q. Le, L. Adrienne Cupples, Emilie S. Zoltick, Megan S. Johnson, Margaret K. Bradbury, Leo B. Waterston, Clara A. Chen, Sara Feldman, Denise L. Perry, Robert C. Green, for the REVEAL Study Group
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 6, Iss 1, Pp n/a-n/a (2020)
Abstract Introduction The safety of predicting conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia using apolipoprotein E (APOE) genotyping is unknown. Methods We randomized 114 individuals with MCI to receive estimat
Externí odkaz:
https://doaj.org/article/70a3ee90dc4b4d9eb0f679eff74edb87
Publikováno v:
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-7 (2018)
Abstract Background Global leaders have set an ambitious goal of developing interventions to effectively treat or prevent Alzheimer’s disease by 2025. Case presentation Achieving this goal will require clinical trials to test promising intervention
Externí odkaz:
https://doaj.org/article/3f2df584ad30401b989899bc21fd0fb5
Publikováno v:
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 10, Iss 1, Pp 285-300 (2018)
Abstract Neuroimaging is advancing a new definition of Alzheimer's disease (AD). Using imaging biomarkers, clinicians may begin to diagnose the disease by identifying pathology and neurodegeneration in either cognitively impaired or unimpaired adults
Externí odkaz:
https://doaj.org/article/7bb8394b76c54f05ad7ae29498350c8a
Autor:
Joshua D. Grill, Jason Karlawish
Publikováno v:
Alzheimer’s Research & Therapy, Vol 9, Iss 1, Pp 1-7 (2017)
Abstract Background In an effort to intervene earlier in Alzheimer’s disease (AD), clinical trials are testing promising candidate therapies in preclinical disease. Preclinical AD trial participants are cognitively normal, functionally independent,
Externí odkaz:
https://doaj.org/article/62617082588f432aaf93d4c6f3810bab